AbbVie's Allergan Aesthetics has secured European approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neurotoxin indicated for glabellar frown lines. Boey's differentiation lies in onset speed and duration profile—a distinct clinical positioning versus Botox (onset 3–7 days, duration 12+ weeks) and Dysport (faster onset, variable duration).
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neurotoxin Reshapes Toxin Economics
Boey (trenibotulinumtoxinE) becomes the first rapid-onset, short-duration neuromodulator approved in Europe, fragmenting the toxin market.
Boey's rapid-onset, short-duration profile fragments the toxin market and signals AbbVie's defense against Revance and Evolus.
For US medspa owners, Boey's EU approval signals AbbVie's intent to fragment the toxin market and defend share against Revance's Daxxify (long-acting) and Evolus's Jeuveau (aggressive rebate pricing). A rapid-onset, short-duration product appeals to patients seeking trial treatments or frequent touch-ups, creating new per-unit volume opportunities—but also cannibalization risk within a practice's existing Botox/Dysport patient base. Watch for US FDA filing; if approved, expect aggressive Alle rebates and MSO bundling to drive adoption.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.